OraPharma, Inc.'s ARESTIN receives accolades

Feb. 13, 2008
Product recognized as one of "The Best Products of the Year" by a leading independent dental research firm.

WARMINSTER, Pennsylvania--OraPharma, Inc., a specialty oral health company producing products for the dental community, has received industry accolades in 2007 for its ARESTIN (minocycline hydrochloride) Microspheres, 1 mg.

The product is an adjunct treatment to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis.

ARESTIN was named as one of the "Products Dental Hygienists Cannot Live Without" by a leading independent, nonprofit dental education and product testing foundation (full report available upon request).

Selected by more than 400 dental teams as a product in the dental professional setting that was most essential and valued by dental professionals, ARESTIN was reported by 78 percent of hygienists as a product they depend on routinely to make their practice "easier, faster, better, and more enjoyable." According to the report, ARESTIN has gained popularity due to "ease of use."

In addition, the same independent, nonprofit foundation named ARESTIN
as one of the best products of the year, receiving the top rating of "Valuable"
based on 79 percent of 30 evaluators stating they would purchase ARESTIN.

"We are extremely proud and excited that ARESTIN was selected by dental professionals as an essential part of their standard of care when treating periodontal disease," remarked John Lenart, OraPharma's Product Director, ARESTIN Marketing. "It's also encouraging to see that our continuing outreach efforts to increase periodontal disease awareness and comprehensive treatment are having a positive effect for clinicians and the patients they treat."

For more information about OraPharma and its products, visit OraPharma.

To read more about ARESTIN, go to ARESTIN.